|
Sponsored by 
|
|
|
|
|
|
|
By Kate Sheridan
Adobe
More often than not, the money fueling biotech is coming from people with jobs that don’t bring them anywhere near a lab bench.
Read More
|
|
By Sharon Begley
Nobel laureate Dr. William Kaelin chatted with STAT readers about his discovery of cells' oxygen-sensing machinery and its role in cancer.
Read More
|
|
By Adam Feuerstein
Kristoffer Tripplaar/SIPA/AP
The deal is part of a plan by Alexion to diversify its pipeline so that future growth is not so heavily reliant on revenue from Soliris and Ultomiris.
Read More
|
|
Sponsor content by EMD Serono
Passionate about creating, improving, and prolonging lives
Fueled by their passion to help create, improve, and prolong lives, EMD Serono is committed to providing meaningful solutions for patients and caregivers impacted by illnesses such as multiple sclerosis, cancer, and infertility. They’re focused on advancing science across oncology, immuno-oncology, and immunology to pave the way to a brighter future. Learn more.
EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
|
|
By Jonathan Saltzman — Boston Globe
APSTOCK
UCB plans to buy Ra Pharmaceuticals, a company that is developing treatments for rare diseases, for about $2.5 billion.
Read More
|
|
By Jonathan Saltzman — Boston Globe
APStock
Blueprint Medicines will receive $25 million to collaborate with French drug maker Ipsen on a potential treatment it developed for a rare genetic disease.
Read More
|
|
